| Translational Track | ||
|---|---|---|
| International Speaker | Talk Title | Highlights |
Dr. Rohan Kamat
|
CMC Considerations for Vector Production for T cell Therapies |
GMP grade viral vectors production, CMC considerations and FDA guidelines for viral vector manufacturing. |
Dr. Arkasubhra Ghosh
|
AAV Vector Designs for Cell Therapy Applications |
AAV Vector Designs, Use of AAV Vector for gene delivery. |
Dr. Everette Nelson
|
Physiological Lentiviral Vectors for Generation of Cell Therapy Products: Challenges, Opportunities and Future Perspectives |
Advantage of using physiological LVs (LVs with regulated expression) over RVs with strong promoters. |
Dr. Debojyoti Chakraborty
|
Crsipr: Cell-line Engineering using Gene Editing Technologies Fast Tracking for Therapeutic Deliveries |
CRISPR as a tool for faster delivery of cell based therapeutic modalities. |
Dr. Raviraja N S
Dr. Lakshmikanth Gandikota
|
Lack of Commercialization in Cell Therapy: Can we Achieve Harmonisation |
Achieving commercialization of cell therapy where India lies far behind. |
| Manufacturing Track | ||
| International Speaker | Talk Title | Highlights |
Dr. Shilpak Chatterjee
|
T Cell Exhaustion : Reversal and Clinical Implications for Cell Therapy Use |
Reversal of T cell exhaustion for longer engraftment, clinical considerations for their use. |
Dr. Albeena Nisar
Dr. Hamenth Kumar Palini
Dr. Nedun Chezhian
Dr. Priyadarshini Chatterjee
Dr. Priya Ramanathan
|
Challenges in Manufacturing of CTPS & Novel Targets/ Strategies for improving the efficacy of Cell Therapies |
Manufacturing challenges associated with cell therapy products, Novel targets for other cancer types and improving efficacy of cell therapy by reducing the exhaustion of T cells by ensuring longer engraftment |
| Regulatory Track | ||
| International Speaker | Talk Title | Highlights |
Dr. Atharva Karulkar
Dr. Geeta Jotwani
Ms. Annam Visala
Mr. Yogananth Rajendran
Dr. Shashwati Basak
|
Regulatory Advice to Guide the Development of the Next Wave of Cell Therapies & the Support from Research Funding Agencies. |
Development of separate guidelines for CAR T cell therapy regulatory requirements, support from Indian research funding agencies like DBT, DST, CSIR, ICMR, etc. |
| Clinical Track | ||
| International Speaker | Talk Title | Highlights |
Dr. Satya Yadav
Dr. (Surg Cdr) Gaurav Narula
Dr. Charanpreet Singh
Dr. Prashant Mehta
Dr. Sunil Bhat
Dr. Nikita Mehra
|
Required changes for the early accessibility of Cell Therapy: Role of Clinical Centres. |
Required changes for the early accessibility of Cell Therapy: Role of Clinical Centres. |
Dr. Uday Kulkarni
|
Fully Automated Decentralized Model of Manufacturing for Clinical Trials & Scale-up Success |
Decentralized model of CAR T manufacturing at point of infusion using fully automated platforms for clinical trials and their subsequent scale up. |
Dr. Chetan Dhamne
|
Natural Killer Cell Therapy and AML |
NK Cells therapeutics for Acute Myeloid Leukemia |
Dr. Lingraj Nayak
|
Preparing for CAR T Cell Therapy: Patient Selection, Bridging Therapies and Lymphodepletion |
Patient screening and eligibility for CAR T cell therapy, bridging therapies, need of lymphodepletion prior to CAR T infusion. |
| Commercialization Track | ||
| International Speaker | Talk Title | Highlights |
Dr. Akhil Kumar
|
Evolving Regulatory Landscape for CAR T & Cell Therapies -The Industry Perspective |
Forming a detailed guideline for speeding up the regulatory process, having a dedicated fast track process for faster regulatory approvals. |
Mr. Shirish Arya
|
Commercial Value of CAR T Cells in India |
Commercializing CAR T cells, making it affordable and accessible for more and more patients. |
Dr. Jogin Desai
|
Lack of Commercialization in Cell Therapy: Can we Achieve Harmonisation |
Achieving commercialization of cell therapy where India lies far behind. |
| Patient Advocacy | ||
| International Speaker | Talk Title | Highlights |
Mrs. Shalini Jatia
Dr. Vandana Dhamankar
Mr Vaggu Raghavendra Goud
Mr. Suraj Nair
|
Equity, Affordability & Access to Cell Therapies |
Affordability of CAR T taking into consideration the COGs and the actual market price. |
| Investor Round | ||
| International Speaker | Talk Title | Highlights |
Dr. Rahul Purwar
Dr. Satyanarayana Chava
|
Lack of Commercialization in Cell Therapy: Can we Achieve Harmonisation |
Achieving commercialization of cell therapy where India lies far behind. |